Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of InMed Pharmaceuticals Inc (NASDAQ: INM) was $0.30 for the day, up 10.99% from the previous closing price of $0.27. In other words, the price has increased by $10.99 from its previous closing price. On the day, 3.39 million shares were traded. INM stock price reached its highest trading level at $0.3366 during the session, while it also had its lowest trading level at $0.27.
Ratios:
Our analysis of INM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.58 and its Current Ratio is at 7.03. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 21 ’24 when HULL ANDREW bought 37,500 shares for $0.39 per share. The transaction valued at 14,625 led to the insider holds 38,258 shares of the business.
ADAMS ERIC A bought 41,600 shares of INM for $14,922 on Feb 20 ’24. The President & CEO now owns 43,959 shares after completing the transaction at $0.36 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INM now has a Market Capitalization of 1835867 and an Enterprise Value of -6577148. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.18 while its Price-to-Book (P/B) ratio in mrq is 0.13. Its current Enterprise Value per Revenue stands at -1.199 whereas that against EBITDA is 0.97.
Stock Price History:
Over the past 52 weeks, INM has reached a high of $2.08, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is -14.85%, while the 200-Day Moving Average is calculated to be -46.05%.
Shares Statistics:
INM traded an average of 307.35K shares per day over the past three months and 624860 shares per day over the past ten days. A total of 3.33M shares are outstanding, with a floating share count of 3.28M. Insiders hold about 1.56% of the company’s shares, while institutions hold 24.17% stake in the company. Shares short for INM as of 1711584000 were 10336 with a Short Ratio of 0.03, compared to 1709164800 on 66159. Therefore, it implies a Short% of Shares Outstanding of 10336 and a Short% of Float of 0.16999999999999998.
Earnings Estimates
On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$6.25. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 1 analysts. It ranges from a high estimate of $1.49M to a low estimate of $1.49M. As of the current estimate, InMed Pharmaceuticals Inc’s year-ago sales were $1.03MFor the next quarter, 1 analysts are estimating revenue of $1.79M. There is a high estimate of $1.79M for the next quarter, whereas the lowest estimate is $1.79M.
A total of 1 analysts have provided revenue estimates for INM’s current fiscal year. The highest revenue estimate was $5.42M, while the lowest revenue estimate was $5.42M, resulting in an average revenue estimate of $5.42M. In the same quarter a year ago, actual revenue was $4.14MBased on 1 analysts’ estimates, the company’s revenue will be $6.77M in the next fiscal year. The high estimate is $6.77M and the low estimate is $6.77M.
